MétaCan
Menu
← Back to cohort

Metformin in early breast cancer (BC): A prospective, open-label, neoadjuvant “window of opportunity” study.

2012· article· en· W2594044276 on OpenAlexaff
Saroj Niraula, Ryan J.O. Dowling, Marguerite Enis, Martin C. Chang, Susan J. Done, Nicky Hood, Jaime Escallón, Wey L. Leong, David R. McCready, Michael Reedijk, Vuk Stambolic, Pamela J. Goodwin

Bibliographic record

VenueJournal of Clinical Oncology · 2012
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicMetabolism, Diabetes, and Cancer
Canadian institutionsMount Sinai HospitalPrincess Margaret Cancer CentreStatistics CanadaOntario Institute for Cancer ResearchUniversity Health NetworkUniversity of Toronto
Fundersnot available
KeywordsMedicineMetforminInternal medicineBreast cancerCancerClinical endpointProspective cohort studyGastroenterologyInsulinOncologyClinical trial

Abstract

fetched live from OpenAlex

1019 Background: There is growing evidence that metformin may exert anti-cancer effects through indirect (insulin-mediated) or direct (insulin-independent) mechanisms. Here, we report final results of a neo-adjuvant “window-of-opportunity” study of metformin in women with operable BC. Methods: Newly diagnosed, untreated, non-diabetic BC patients received metformin 500 mg tid after diagnostic core-biopsy until definitive surgery(no other treatment). Clinical [weight, symptoms, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C-30)] and biologic characteristics [insulin, glucose, homeostatic model assessment (HOMA), C-reactive protein (CRP), leptin] were compared pre- and post-metformin as were Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL, an apoptotic marker) and Ki67 (primary end-point) scored blinded by manual count of positive nuclear-staining. The planned sample-size of 40 patients gave 90% power to detect a 5.5 percentage point change in Ki67. Results: Thirty-nine patients were enrolled and mean age was 51 years; metformin was given for 18 days (median), range 13-40 days. Twenty patients had T1 and 19 T2/T3 tumors; 16 tumors were grade III; 24 were N0; 32 ER/PR positive, 5 HER-2 positive. Grade 1-2 self-limiting diarrhea, anorexia and abdominal distention occurred in 50%, 41% and 32%. EORTC QLQ scores were stable in all function domains and overall scores. Main study outcomes are tabulated here. Conclusions: Short-term preoperative metformin was well-tolerated and resulted in clinical and cellular effects in keeping with beneficial anti-cancer effects as demonstrated by improved insulin resistance (HOMA), decreased proliferation (ki67) and increased apoptosis (TUNEL). [Table: see text]

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.013

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.001
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0000.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.002
Insufficient payload (model declined to judge)0.0030.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.142
GPT teacher head0.472
Teacher spread0.330 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicMetabolism, Diabetes, and Cancer→French-language works237,207→